心可舒片与普罗帕酮联合治疗冠状动脉粥样硬化性心脏病心律失常的疗效与安全性  

Efficacy and Safety of Xinkeshu Tablets Combined with Propafenone in the Treatment of Ar⁃rhythmia in Coronary Atherosclerotic Heart Disease

作　　者：李晶晶 汤佩[2] 汪帅 LI Jingjing;TANG Pei;WANG Shuai(Department of Cardiovascular Medicine,Hong'an County People's Hospital,Huanggang 438400,Hubei,China;Department of Cardiothoracic Surgery,Hong'an County People's Hospital,Huanggang 438400,Hubei,China;Department of Traditional Chinese Medicine,Hong'an County People's Hospital,Huanggang 438400,Hubei,China)

机构地区：[1]红安县人民医院心血管内科,湖北黄冈438400 [2]红安县人民医院心胸外科,湖北黄冈438400 [3]红安县人民医院中医科,湖北黄冈438400

出　　处：《世界复合医学(中英文)》2025年第2期32-36,共5页World Journal of Complex Medicine

摘　　要：目的研究心可舒片与普罗帕酮联合治疗冠状动脉粥样硬化性心脏病心律失常的疗效及安全性。方法选取2022年6月—2024年6月红安县人民医院收治的200例冠状动脉粥样硬化性心脏病心律失常患者为研究对象,按照不同的治疗方法分为两组,每组100例,西医组接受普罗帕酮治疗,联合组采用普罗帕酮联合心可舒片治疗。对比两组中医证候积分、心功能、24 h心电图参数以及不良反应发生率。结果治疗后,两组中医证候积分均较治疗前降低,且联合组中医证候(心悸不宁、胸中窒闷、心前区窒痛或刺痛、气短乏力)积分均低于西医组,差异均有统计学意义(P均<0.05)。治疗后,两组心功能均较治疗前改善,且联合组左心室舒张末期内径、左心室射血分数、心输出量均优于西医组,差异均有统计学意义(P均<0.05)。治疗后,两组24 h心电图参数均较治疗前改善,且联合组室性早搏数量、室性心动过速数量、QT离散度、校正QT间期均低于西医组,差异均有统计学意义(P均<0.05)。联合组不良反应发生率为4.00%(4/100),低于西医组的12.00%(12/100),差异有统计学意义(χ2=4.348,P<0.05)。结论盐酸普罗帕酮片结合心可舒片的协同治疗策略在冠状动脉粥样硬化性心脏病心律失常的治疗中疗效显著,改善了患者的中医证候积分、心功能及心电图参数,并且安全性较高。Objective To study the efficacy and safety of the combined treatment of arrhythmia in coronary atherosclerotic heart disease with Xinkeshu Tablets and propafenone.Methods A total of 200 patients with arrhythmia in coronary atherosclerotic heart disease admitted to Hong'an County People's Hospital from June 2022 to June 2024 were selected as the research objects.According to different treatment methods,they were divided into two groups,100 cases in each group.The Western medicine group was treated with propafenone,and the combined group was treated with propafenone combined with Xinkeshu Tablets.The traditional Chinese medicine syndrome scores,cardiac function,24 h electrocardiogram parameters and incidence of adverse reactions were compared between the two groups.Results After treatment,the scores of traditional Chinese medicine syndromes in the two groups were lower than those before treatment,and the scores of traditional Chinese medicine syndromes(palpitations,chest suffocation,precordial suffocation or tingling,shortness of breath and fatigue)in the combined group were lower than those in the Western medicine group,the differences were statistically significant(all P<0.05).After treatment,the cardiac function of the two groups was improved compared with that before treatment,and the left ventricular end-diastolic internal diameter,left ventricular ejection fraction,cardiac output of the combined group were better than those of the Western medicine group,the differences were statistically significant(all P<0.05).After treatment,the 24 h electrocardiogram parameters of the two groups were improved compared with those before treatment,and the number of ventricular premature beats,the number of ventricular tachycardia,QT dispersion and corrected QT interval in the combined group were lower than those in the Western medicine group,the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the combined group was 4.00%(4/100),which was lower than 12.00%(12/100)in the Western med

关 键 词：心可舒片 盐酸普罗帕酮片 冠状动脉粥样硬化性心脏病心律失常 疗效 安全性 

分 类 号：R541.4[医药卫生—心血管疾病] R541.7[医药卫生—内科学]